DiabetologyNews.net

Diabetology Xagena

Combination treatment with a glucagon-like peptide-1 ( GLP-1 ) agonist and basal Insulin has been proposed as a treatment strategy for type 2 diabetes mellitus that could provide robust glucose-loweri ...


The efficacy and safety of Lixisenatide ( Lyxumia ), a once-daily prandial glucagon-like peptide-1 ( GLP-1 ) receptor agonist, in older patients with type 2 diabetes mellitus ( T2DM ) insufficiently c ...


The development of common diabetes complications that can lead to blindness and amputations could be reduced by taking statins, indicates new research published in The Lancet Diabetes & Endocrinol ...


Small cross-sectional studies have suggested that Metformin, a first-line oral hypoglycemic agent, may lower thyroid-stimulating hormone ( TSH ) levels. The objective of a study was to determine whe ...


The extent to which change in physical activity can modify the risk of cardiovascular disease in individuals at high cardiovascular risk is uncertain. Researchers have investigated whether baseline ...


Since protein ingestion is known to stimulate the secretion of glucagon-like peptide-1 ( GLP-1 ), researchers have hypothesised that enhancing GLP-1 secretion to harness its insulinotropic / beta cell ...


Diabetes mellitus is a leading cause of chronic kidney disease ( CKD ) worldwide. Optimum glycaemic control in patients with type 2 diabetes is important to minimise the risk of microvascular and macr ...


An observational study has shown that patients with type 2 diabetes mellitus treated with a combination of Sitagliptin and Metformin initiated Insulin therapy at a slower rate during the period of obs ...


When patients with type 2 diabetes mellitus start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 ( GLP-1 ) receptor agonists and basal insulins. In DURATION-3, ...


Although carbohydrate counting is the recommended dietary strategy for achieving glycaemic control in people with type 1 diabetes mellitus, the advice is based on narrative review and grading of the a ...


Previous studies have yielded conflicting results about the association between incretin therapies and acute pancreatitis. Researchers have compared the occurrence of acute pancreatitis in a populatio ...



Results from an observational study that has assessed the differences in time to initiation of Insulin use and the proportion of the population initiating Insulin among patients with type 2 diabetes t ...


The objective of a study was to evaluate the pharmacokinetics, efficacy and safety of Lixisenatide ( subcutaneous injection ) ( Lyxumia ) in elderly ( greater than or equal to 65 years old ) and very ...


Patients were twice as likely to have a diabetic foot ulcer heal within eight weeks when they were treated with a tissue repair drug versus a placebo, according to new research published in the Journa ...


Researchers have compared stepwise addition of bolus Insulin with a full basal-bolus regimen in patients with type 2 diabetes inadequately controlled on basal Insulin plus oral antidiabetic drugs. ...


Vitamin D is known as a major regulator of calcium levels and bone metabolism. Furthermore, it also influences the immune system. Previous studies have shown that patients with recently diagnosed type ...


The aim was to assess the efficacy and safety of Dapagliflozin ( Forxiga ) as add-on therapy in patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase-4 inhibitor w ...


Metformin ( Glucophage ) is the only first-line oral hypoglycaemic drug for type 2 diabetes recommended by international guidelines with proven efficacy, safety, and cost-effectiveness. However, littl ...


According to research published in Diabetologia, the journal of the European Association for the Study of Diabetes, people who have diabetes at the time they are diagnosed with cancer are more likely ...


New research published in Diabetologia, the journal of the European Association for the Study of Diabetes ( EASD ), has shown that diabetes mellitus in women is associated with an increased risk of st ...


Clinical trials have demonstrated that Metformin increases the efficiency of systemic therapy in cancer patients. Researchers examined whether the efficacy of conventional treatment of differentiat ...


The aim of the study was to investigate the long-term safety and efficacy of Empagliflozin ( Jardiance ), a sodium glucose cotransporter 2 inhibitor ( SGLT2 ); Sitagliptin ( Januvia ); and Metformin ( ...


Glucagon-like peptide-1 receptor agonists Exenatide ( Byetta ) and Liraglutide ( Victoza ) have been shown to improve glycaemic control and reduce bodyweight in patients with type 2 diabetes.The effic ...


The cardiovascular safety and efficacy of many current antihyperglycemic agents, including Saxagliptin ( Onglyza ), a dipeptidyl peptidase 4 ( DPP-4 ) inhibitor, are unclear.Researchers have randomly ...


Researchers at the National Institutes of Health have clarified in rodent and test tube experiments the role that inflammation plays in type 2 diabetes, and revealed a possible molecular target for tr ...


Diabetes is a risk factor for dementia. It is unknown whether higher glucose levels increase the risk of dementia in people without diabetes mellitus.Researchers used 35,264 clinical measurements of g ...


Guidelines suggest setting individualised targets for glycaemic control in elderly patients with type 2 diabetes, despite no evidence.The aim of the study ( INTERVAL ) was to assess the feasibility of ...


Studies have shown that, when implemented early in the course of type 2 diabetes mellitus, treatment with intensive Insulin therapy for 2-3 weeks can induce a glycaemic remission, wherein patients are ...


Effective reduction of albuminuria and blood pressure in patients with type 2 diabetes mellitus who have nephropathy is seldom achieved with available treatments. Researchers tested the effects of tre ...


The FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new class of medications called sodium glu ...


The European Medicines Agency ( EMA ) has completed a review of new data on the cancer risk with Insulin glargine-containing medicines. The Agency’s Committee for Medicinal Products for Human Use ( CH ...


New data from a Phase IV study evaluating Linagliptin ( 5 mg ) as monotherapy and in combination with Metformin ( 1500 or 2000 mg ) in treatment-naive adults with newly diagnosed ( less than 12 months ...


The results from a new pooled analysis of phase III data for the dipeptidyl peptidase-4 ( DPP-4 ) inhibitor Linagliptin ( Trajenta ) were presented at the American Diabetes Association ( ADA ) 73rd Sc ...


The EMA ( European Medicines Agency ) is investigating findings by a group of independent academic researchers that suggest an increased risk of pancreatitis ( inflammation of the pancreas ) and preca ...


The results from a new study in which Linagliptin ( Tradjenta ), a DPP-4 inhibitor, has demonstrated statistically significant reductions in blood glucose levels ( HbA1c ) after 12 weeks ( primary end ...


The results of a 52-week phase III clinical trial of Empagliflozin, presented at the American Diabetes Association ( ADA ) 73rd Scientific Sessions, showed statistically significant reductions in HbA1 ...


The results of a 24-week phase III clinical trial, which showed that treatment with the investigational compound Empagliflozin as monotherapy produced statistically significant reductions in HbA1c ver ...


The results of two phase III 24-week clinical trials of the investigational agent Empagliflozin added to Metformin with and without the addition of sulfonylurea, in people with type 2 diabetes ( T2D ) ...


The results from two phase III clinical studies that showed Linagliptin ( Tradjenta ) in Asian adults, as monotherapy and in combination with Metformin, improved blood glucose control in people with t ...


The results of a 78-week phase III clinical trial of the investigational agent Empagliflozin as add-on to basal Insulin in adults with type 2 diabetes ( T2D ), presented at the American Diabetes Assoc ...


The results from two exploratory analyses assessing the risk of hypoglycemia with Linagliptin ( Tradjenta ) treatment in adults with type 2 diabetes ( T2D ), were presented.In an exploratory analysis ...


The FDA ( Food and Drug Administration ) has approved updates to the full U.S. Prescribing Information ( PI ) for Tradjenta ( Linagliptin ) tablets and Jentadueto ( Linagliptin and Metformin hydrochlo ...


Positive top-line results of two additional phase III AWARD trials for Dulaglutide, an investigational, long-acting glucagon-like peptide 1 ( GLP-1 ) receptor agonist being studied as a once-weekly tr ...


The American College of Physicians ( ACP ) has developed a guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of type 2 diabetes medicat ...


The American College of Physicians ( ACP ) has developed a guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of type 2 diabetes medicat ...


Sanofi-Aventis has announced that Lixisenatide ( Lyxumia ) once-daily achieved primary efficacy endpoint and fewer hypoglycemias versus Exenatide ( Byetta ) twice-daily. The GetGoal-X Phase III stu ...


Use of established fracture prediction methods in older patients with type 2 diabetes mellitus found that scores from these methods were associated with hip and non-spine fracture risk, and a certain ...


Results from an investigational phase 3b clinical study have shown that Onglyza ( Saxagliptin ) 5 mg added to Insulin ( with or without Metformin ) significantly reduced glycosylated hemoglobin levels ...


Patients with systemic inflammatory conditions, such as rheumatoid arthritis and psoriasis, experience a 1.5 to 2-fold increased rate of cardiovascular disease. Previous research suggests that inflamm ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati